查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950445

黑色素瘤联合治疗市场（按联合治疗类型、治疗阶段、疾病分期、给药途径和最终用户划分）—全球预测，2026-2032年

Combination Therapies for Melanoma Market by Combination Regimen Type, Line Of Therapy, Disease Stage, Administration Route, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年黑色素瘤联合治疗市场价值为 47.8 亿美元，预计到 2026 年将成长至 53.8 亿美元，年复合成长率为 12.98%，到 2032 年将达到 112.5 亿美元。

关键市场统计数据
基准年 2025 47.8亿美元
预计年份：2026年 53.8亿美元
预测年份 2032 112.5亿美元
复合年增长率 (%) 12.98%

策略性介绍，展示联合治疗如何透过生物协同作用、运作要务和价值主导的临床路径重塑黑色素瘤治疗。

联合治疗正在重新定义黑色素瘤的临床治疗方案，开启了一个以治疗协同作用和生物学原理指导治疗选择和顺序的新时代。近年来，临床医生和研究人员越来越重视将免疫查核点抑制剂与标靶通路抑制剂或细胞毒性药物联合使用的治疗方案，以提高治疗反应的持久性，克服抗药性机制，并扩大获益患者群体。这种转变源于对肿瘤-免疫系统相互作用、黑色素瘤基因组驱动因素以及肿瘤微环境在调节治疗反应中的作用等方面的更清晰的机制理解。

免疫肿瘤学、精准诊断和治疗模式的进步正在汇聚，从而为黑色素瘤治疗标准和相关人员的期望带来模式转移。

免疫肿瘤学、标靶治疗和精准医学的融合发展正在改变黑色素瘤的治疗模式。新型联合治疗不仅拓展了治疗选择，也促使人们重新思考临床终点、监管路径和治疗标准。新出现的证据正在改变人们对疗效深度和持续时间的预期，将长期疾病控製作为核心目标，并推动临床试验设计转向维持治疗策略和富含生物标记的队列研究。

评估2025年美国关税环境以及贸易政策变化对供应链、製造策略和临床项目连续性的影响

2025年美国关税政策对黑色素瘤联合治疗的生态系统产生了多方面的影响，波及临床供应链、生产策略和商业计划。活性药物成分、特殊生物製药和先进生产设备的进口成本增加，可能导致生产费用上升，库存管理难度增加。为应对这项挑战，製造商和合约合作伙伴可能会加快供应链的地域多角化，投资本地生产能力，并重新谈判供应商协议，以确保临床试验用药的持续供应和商业性供应。

基于全面细分的洞察，阐明治疗方法类型、治疗线数、疾病阶段、给药途径和医疗环境对临床和商业策略的影响。

市场区隔洞察揭示了不同治疗方法类型、治疗线数、疾病分期、给药途径和医疗环境所带来的细微机会和临床考量。联合治疗方案包括免疫疗法合併化疗、免疫疗法合併标靶治疗以及标靶治疗合併化疗，其中免疫化疗合併化疗又可细分为CTLA-4抑制剂合併化疗和PD-1抑制剂合併化疗。免疫疗法合併标分子标靶治疗联合治疗可进一步细分为CTLA-4抑制剂合併BRAF抑制剂、PD-1抑制剂合併BRAF抑制剂以及PD-1抑制剂合併MEK抑制剂。同时，分子标靶治疗合併化疗方案包括BRAF抑制剂合併化疗和MEK抑制剂合併化疗。这些治疗方案层面的差异表明，不同治疗中心在安全性管理、生物标记检测要求和操作部署方面存在差异。

区域趋势以及监管、支付方和基础设施的考虑正在影响全球市场黑色素瘤联合治疗的推广路径。

区域趋势对黑色素瘤联合治疗在全球市场的研发、核准和应用有显着影响。在美洲，监管路径和支付方框架强调生存获益和真实世界疗效的证据，并据此调整试验设计和市场进入资料。该地区的卓越中心和强大的肿瘤网络正在促进输注联合治疗的快速应用，但都市区地区在可及性方面的差异仍然是营运方面的挑战。欧洲、中东和非洲的情况则更为复杂，各地区的报销流程和卫生技术评估要求存在差异，因此需要製定针对特定区域的证据产生和定价策略。各国诊断基础设施和转诊模式的差异也导致各次区域应用速度和范围的差异。

影响联合治疗开发、供应弹性、诊断整合和上市后核准产生的企业策略和伙伴关係模式

推动联合治疗趋势的关键企业层面倡议反映了不断演变的产品系列、策略联盟以及对临床开发和生产的重点投资。领先的生物製药和专科药物开发公司正在製定差异化的联合治疗策略，将免疫查核点抑制剂与标靶治疗治疗药物或化疗结合，利用互补的作用机制来增强抗肿瘤活性。大型製药企业与小型创新企业之间的策略联盟正在加速新型作用机制的普及，同时实现研发风险共用和临床能力的拓展。同时，各公司正在投资伴随诊断合作，以实现基于生物标记的患者筛选，并提升支付方的价值提案。

为开发商和供应商提供切实可行的综合策略，以加强联合治疗试验设计、供应弹性、支付方合作和试验中心准备。

产业领导者应采取一系列切实可行的措施，将科学潜力转化为持续的临床和商业性成果。首先，将临床开发策略与生物标记指导的患者选择相结合，将提高获得显着获益的可能性，同时有助于与支付方进行价值评估。申办者可以采用适应性试验设计，并纳入转换终点，以加速启动/终止试验的决策，并优化联合治疗的顺序。其次，透过区域製造伙伴关係和采购多元化来增强供应链韧性，可以降低贸易政策波动和零件短缺带来的营运风险。

采用透明的调查方法，结合临床证据综合、专家访谈和情境分析，检验了关于联合治疗采纳和价值驱动因素的研究结果。

本执行摘要的调查方法结合了多个高品质证据来源的三角验证、结构化的专家参与以及严谨的分析框架，以确保其稳健性和相关性。临床证据综合分析纳入了同行评审文献、官方监管文件和正在进行的临床试验註册信息，以了解组合方案的疗效和安全性趋势。营运和商业洞察是基于对临床医生、试验负责人、医院药剂师和支付方的访谈，从而能够对推广应用障碍和实施需求进行切实评估。

摘要强调，整合科学、商业和商业性营运的方法对于充分发挥黑色素瘤联合治疗的潜力至关重要。

总之，黑色素瘤联合治疗代表了肿瘤学领域的一项重大进展，其特点是生物学上合理​​的药物组合、操作上的复杂性以及相关人员不断变化的期望。联合疗法的成功应用需要协调一致的策略，整合精准诊断、适应性临床开发、稳健的生产製造以及积极的医保支付方合作。儘管临床进展拓展了获得更深层次、更持久疗效的可能性，但这些进展能否在常规实践中得到充分发挥，取决于医疗系统的准备情况、便捷的准入途径以及持续的证据积累，以证明其长期价值。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8.依联合治疗类型分類的黑色素瘤联合治疗市场

  • 免疫疗法+化疗
    • CTLA-4抑制剂合併化疗
    • PD-1抑制剂+化疗
  • 免疫疗法+分子标靶药物疗法
    • CTLA-4抑制剂+BRAF抑制剂
    • PD-1抑制剂+BRAF抑制剂
    • PD-1抑制剂+MEK抑制剂
  • 分子标靶药物治疗与化疗结合
    • BRAF抑制剂+化疗
    • MEK抑制剂+化疗

9.按治疗线分類的黑色素瘤联合治疗市场

  • 一线治疗
  • 二级治疗
  • 三线及以后

10.依疾病阶段分類的黑色素瘤联合治疗市场

  • 进行性黑色素瘤
  • 转移性黑色素瘤
  • 无法切除的黑色素瘤

11.依给药途径分類的黑色素瘤联合治疗市场

  • 静脉注射
  • 口服

12.按最终用户分類的黑色素瘤联合治疗市场

  • 门诊手术中心
  • 医院
  • 专科诊所

13.按地区分類的黑色素瘤联合治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14.按组别分類的黑色素瘤联合治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国黑色素瘤联合治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国黑色素瘤联合治疗市场

第十七章：中国黑色素瘤联合治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Array BioPharma Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Immunocore Holdings plc
  • Incyte Corporation
  • Iovance Biotherapeutics, Inc.
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • OncoSec Medical Incorporated
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Replimune Group, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4F7A6D4FD86B

The Combination Therapies for Melanoma Market was valued at USD 4.78 billion in 2025 and is projected to grow to USD 5.38 billion in 2026, with a CAGR of 12.98%, reaching USD 11.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.78 billion
Estimated Year [2026] USD 5.38 billion
Forecast Year [2032] USD 11.25 billion
CAGR (%) 12.98%

A strategic introduction framing how combination regimens are reshaping melanoma care through biologic synergy, operational demands, and value-driven clinical pathways

Combination therapies have redefined the clinical approach to melanoma, driving an era in which therapeutic synergy and biologic rationale guide treatment selection and sequencing. Over recent years clinicians and researchers have increasingly prioritized regimens that pair immune checkpoint modulation with targeted pathway inhibition or cytotoxic agents in order to enhance response durability, overcome resistance mechanisms, and broaden the population of patients who derive clinical benefit. These shifts are underpinned by a clearer mechanistic understanding of tumor-immune interactions, the genomic drivers of melanoma, and the tumor microenvironment's role in modulating therapeutic efficacy.

As stakeholders evaluate the next wave of therapeutic strategies, multidisciplinary teams must reconcile efficacy signals with tolerability profiles, real-world delivery constraints, and payer expectations. Consequently, integration of translational biomarkers, adaptive trial designs, and patient-centric endpoints has become essential for demonstrating differentiated value. Moreover, health systems are adapting care pathways to manage complex infusion regimens, oral targeted agents, and the unique safety management needs of combination approaches. Taken together, the introduction frames an industry transitioning from monotherapy paradigms toward personalized combination strategies that require coordinated clinical, operational, and commercial planning.

How converging advances in immuno-oncology, precision diagnostics, and delivery models are driving a paradigm shift in melanoma treatment standards and stakeholder expectations

The landscape of melanoma treatment is undergoing transformative shifts driven by converging advances in immuno-oncology, targeted therapy, and precision medicine. Novel combinations are not only expanding therapeutic options but are also prompting reassessment of clinical endpoints, regulatory pathways, and standards of care. Emerging evidence has altered expectations around depth and duration of response, elevating long-term disease control as a central objective and shifting clinical trial design toward maintenance strategies and biomarker-enriched cohorts.

In parallel, advances in genomic profiling and immune monitoring are enabling more precise pairing of agents to patient subpopulations, which in turn fosters development of adaptive treatment algorithms. Delivery innovations, including optimized oral-targeted regimens and infusion-sparing schedules, are reducing patient burden while intensifying the focus on toxicity mitigation and health-system readiness. Commercially, payers and providers increasingly demand robust real-world evidence and value frameworks that capture both clinical benefit and the resource implications of combination care. These combined forces are redefining competitive dynamics, accelerating partnerships across biotech and biopharma, and necessitating nimble strategies for clinical development and market access.

Assessment of the 2025 United States tariff environment and how trade policy shifts are reshaping supply chains, manufacturing strategies, and clinical program continuity

The implementation of tariffs in the United States during 2025 has multifaceted implications for the ecosystem supporting combination therapies for melanoma, affecting clinical supply chains, manufacturing strategies, and commercial planning. Increased import costs for active pharmaceutical ingredients, specialized biologic components, and advanced manufacturing equipment can raise production expenses and complicate inventory management. In response, manufacturers and contract partners may accelerate regional diversification of supply networks, invest in local manufacturing capacity, or renegotiate supplier contracts to maintain continuity of clinical trial supplies and commercial availability.

Beyond direct cost pressures, tariffs influence procurement timelines and capital allocation decisions for drug developers and service providers. Sponsors may prioritize consolidation of manufacturing footprints or pursue vertical integration to insulate critical production steps from tariff volatility. Health systems and specialty pharmacies could experience downstream effects through changes in pricing dynamics or the availability of specific agents, prompting adjustments in formulary management and therapeutic sequencing. Importantly, regulatory and trade policy shifts also affect international clinical collaboration, as cross-border movement of investigational products and biospecimens becomes more administratively complex. Organizations that proactively model tariff scenarios and incorporate supply-chain resilience into program planning will be better positioned to sustain clinical programs and commercial launches under evolving trade conditions.

Comprehensive segmentation-driven insights that clarify how regimen types, therapy lines, disease stages, administration routes, and care settings influence clinical and commercial strategy

Insight into market segmentation reveals nuanced opportunities and clinical considerations across regimen types, lines of therapy, disease stages, administration routes, and care settings. Combination regimen types encompass immunotherapy plus chemotherapy, immunotherapy plus targeted therapy, and targeted therapy plus chemotherapy, with the immunotherapy plus chemotherapy category further differentiated into CTLA-4 inhibitor plus chemotherapy and PD-1 inhibitor plus chemotherapy. Immunotherapy plus targeted therapy is further parsed into CTLA-4 inhibitor plus BRAF inhibitor, PD-1 inhibitor plus BRAF inhibitor, and PD-1 inhibitor plus MEK inhibitor combinations, while targeted therapy plus chemotherapy includes BRAF inhibitor plus chemotherapy and MEK inhibitor plus chemotherapy constructs. These regimen-level distinctions inform divergent safety management profiles, biomarker testing requirements, and operational deployment across treatment centers.

Line of therapy segmentation spans first-line therapy, second-line therapy, and third-line therapy and beyond, each presenting distinct evidence thresholds and reimbursement dynamics. Disease stage segmentation differentiates between advanced melanoma, metastatic melanoma, and unresectable melanoma, which affects patient selection, clinical outcome expectations, and trial eligibility criteria. Administration route segmentation contrasts intravenous administration with oral administration, shaping adherence, monitoring burdens, and site-of-care decisions. End-user segmentation includes ambulatory surgical centers, hospitals, and specialty clinics, with each care setting offering divergent capacity for infusion services, supportive care, and multidisciplinary coordination. By synthesizing these dimensions, stakeholders can identify where clinical need aligns with operational capacity and where targeted investments in diagnostics, nurse education, or patient navigation will yield the greatest impact.

Regional dynamics and regulatory, payer, and infrastructure considerations that determine adoption pathways for combination melanoma therapies across global markets

Regional dynamics materially influence how combination therapies for melanoma are developed, approved, and adopted across global markets. In the Americas, regulatory pathways and payer frameworks emphasize evidence of survival benefit and real-world effectiveness, shaping trial design and market-access dossiers accordingly. Centers of excellence and robust oncology networks in this region facilitate rapid adoption of infusion-based combinations, while disparities in access between urban and rural settings remain an operational challenge. Europe, Middle East & Africa present a heterogeneous landscape in which divergent reimbursement processes and health technology assessment requirements necessitate regionally tailored evidence generation and pricing strategies. National differences in diagnostic infrastructure and referral patterns create variation in the speed and extent of adoption across subregions.

Asia-Pacific offers a diverse set of opportunities driven by rising investment in oncology care, rapid expansion of genomic testing capacity, and large patient populations with unique epidemiologic profiles. Regulatory harmonization efforts and growing local manufacturing capabilities influence launch sequencing and partnership models in the region. Across all regions, connectivity between clinical trial networks, payer expectations, and infrastructure for safe administration will determine how swiftly new combination regimens transition from approval to routine use. Stakeholders must therefore align development plans with regional regulatory standards, evidence requirements, and health-system capabilities to optimize uptake and patient outcomes.

Company strategies and partnership models that are shaping combination regimen development, supply resilience, diagnostic integration, and post-approval evidence generation

Key company-level dynamics driving the combination therapy landscape reflect evolving portfolios, strategic alliances, and targeted investments in clinical development and manufacturing. Leading biopharmaceutical firms and specialty developers are differentiating through combination strategies that pair immune checkpoint modulators with targeted agents or chemotherapies, leveraging complementary mechanisms to enhance antitumor activity. Strategic collaborations between large pharmas and smaller innovators accelerate access to novel mechanisms while enabling shared development risk and expanded clinical capacity. Concurrently, companies are investing in companion diagnostic partnerships to enable biomarker-driven patient selection and to support payer-facing value propositions.

Operationally, companies are optimizing supply chains, scaling biologics manufacturing, and enhancing pharmacovigilance systems to manage the safety complexity inherent in multi-agent regimens. Portfolio prioritization often emphasizes late-stage combinations supported by robust translational science and manageable toxicity profiles. Some organizations are pursuing label expansions and adaptive regulatory strategies to secure earlier access pathways in specific patient subgroups. Competitive differentiation will increasingly rely on post-approval evidence generation, real-world outcomes initiatives, and services that improve patient adherence and manage adverse events, thereby demonstrating total value beyond traditional clinical trial endpoints.

Practical and integrated measures for developers and providers to strengthen trial design, supply resilience, payer engagement, and site readiness for combination therapies

Industry leaders should pursue a set of actionable measures to translate scientific promise into durable clinical and commercial outcomes. First, aligning clinical development strategies with biomarker-driven patient selection will enhance the probability of meaningful benefit while supporting payer conversations on value. Sponsors should adopt adaptive trial designs and incorporate translational endpoints to accelerate go/no-go decisions and to refine combination sequencing. Second, strengthening supply-chain resilience through regional manufacturing partnerships and diversified sourcing will mitigate the operational risks introduced by trade policy fluctuations and component shortages.

Third, investing in multidisciplinary site readiness-including infusion capacity, toxicity management training, and patient navigation-will improve real-world implementation and adherence. Fourth, engaging payers early to define acceptable evidence packages, outcomes-based contracting parameters, and real-world data collection priorities will streamline reimbursement pathways. Finally, companies should commit to sustained post-approval evidence generation and health-economic modeling to demonstrate long-term value, manage expectations around toxicity and cost, and support broad access across heterogeneous health systems. Collectively, these actions create an integrated approach that spans discovery, development, and delivery, enabling therapies to reach the right patients efficiently and sustainably.

A transparent methodology combining clinical evidence synthesis, expert interviews, and scenario analysis to validate insights on combination therapy deployment and value drivers

The research methodology for this executive summary combined triangulation of multiple high-quality evidence streams, structured expert engagement, and rigorous analytical frameworks to ensure robustness and relevance. Clinical evidence synthesis incorporated peer-reviewed literature, public regulatory filings, and registries of ongoing trials to capture efficacy and safety trends across combination regimens. Operational and commercial insights were informed by interviews with clinicians, trial operations leads, hospital pharmacists, and payers, enabling pragmatic assessment of adoption barriers and implementation needs.

Analytically, the approach employed cross-sectional mapping of regimen typologies against line-of-therapy and disease-stage considerations, together with scenario analysis to evaluate the impact of supply-chain disruptions and trade policy shifts. Validation steps included reconciliation of primary findings with expert reviewers and sensitivity testing of key assumptions related to administration route preferences and site-of-care capacities. Limitations are acknowledged, including the evolving nature of clinical data and regional variability in regulatory and reimbursement environments; nonetheless, the methodology emphasizes evidence convergence and practical applicability to inform strategic decision-making.

Concluding synthesis highlighting how integrated scientific, operational, and commercial approaches are essential to realize the promise of combination melanoma therapies

In conclusion, combination therapies for melanoma represent a pivotal evolution in oncology, characterized by biologically rational pairings, operational complexity, and evolving stakeholder expectations. Successful deployment requires harmonized strategies that integrate precision diagnostics, adaptive clinical development, resilient manufacturing, and proactive payer engagement. While clinical advances expand the potential to achieve deeper and more durable responses, their realization in routine practice depends on health-system readiness, access pathways, and sustained evidence generation that demonstrates long-term value.

As organizations navigate regulatory variability, supply-chain pressures, and the need for differentiated real-world outcomes, those that align scientific innovation with pragmatic commercialization and care-delivery strategies will gain competitive advantage. Ongoing monitoring of policy shifts, regional infrastructure developments, and emergent clinical data will remain essential to refine approaches and to ensure that combination regimens translate into meaningful improvements in patient outcomes and health-system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Combination Therapies for Melanoma Market, by Combination Regimen Type

  • 8.1. Immunotherapy Plus Chemotherapy
    • 8.1.1. Ctla4 Inhibitor Plus Chemotherapy
    • 8.1.2. Pd1 Inhibitor Plus Chemotherapy
  • 8.2. Immunotherapy Plus Targeted Therapy
    • 8.2.1. Ctla4 Inhibitor Plus Braf Inhibitor
    • 8.2.2. Pd1 Inhibitor Plus Braf Inhibitor
    • 8.2.3. Pd1 Inhibitor Plus Mek Inhibitor
  • 8.3. Targeted Therapy Plus Chemotherapy
    • 8.3.1. Braf Inhibitor Plus Chemotherapy
    • 8.3.2. Mek Inhibitor Plus Chemotherapy

9. Combination Therapies for Melanoma Market, by Line Of Therapy

  • 9.1. First-Line Therapy
  • 9.2. Second-Line Therapy
  • 9.3. Third-Line Therapy And Beyond

10. Combination Therapies for Melanoma Market, by Disease Stage

  • 10.1. Advanced Melanoma
  • 10.2. Metastatic Melanoma
  • 10.3. Unresectable Melanoma

11. Combination Therapies for Melanoma Market, by Administration Route

  • 11.1. Intravenous Administration
  • 11.2. Oral Administration

12. Combination Therapies for Melanoma Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Combination Therapies for Melanoma Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Combination Therapies for Melanoma Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Combination Therapies for Melanoma Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Combination Therapies for Melanoma Market

17. China Combination Therapies for Melanoma Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Agenus Inc.
  • 18.7. Amgen Inc.
  • 18.8. Array BioPharma Inc.
  • 18.9. Bayer AG
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Eisai Co., Ltd.
  • 18.13. Exelixis, Inc.
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Immunocore Holdings plc
  • 18.16. Incyte Corporation
  • 18.17. Iovance Biotherapeutics, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Nektar Therapeutics
  • 18.20. Novartis AG
  • 18.21. OncoSec Medical Incorporated
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals, Inc.
  • 18.24. Replimune Group, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY CTLA4 INHIBITOR PLUS CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY CTLA4 INHIBITOR PLUS CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY CTLA4 INHIBITOR PLUS CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY CTLA4 INHIBITOR PLUS BRAF INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY CTLA4 INHIBITOR PLUS BRAF INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY CTLA4 INHIBITOR PLUS BRAF INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS BRAF INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS BRAF INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS BRAF INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS MEK INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS MEK INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY PD1 INHIBITOR PLUS MEK INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY BRAF INHIBITOR PLUS CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY BRAF INHIBITOR PLUS CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY BRAF INHIBITOR PLUS CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY MEK INHIBITOR PLUS CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY MEK INHIBITOR PLUS CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY MEK INHIBITOR PLUS CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY FIRST-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY FIRST-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SECOND-LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SECOND-LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY THIRD-LINE THERAPY AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY THIRD-LINE THERAPY AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY THIRD-LINE THERAPY AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADVANCED MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADVANCED MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY METASTATIC MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY METASTATIC MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY UNRESECTABLE MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY UNRESECTABLE MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY UNRESECTABLE MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY COMBINATION REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY TARGETED THERAPY PLUS CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA COMBINATION THERAPIES FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)